公开(公告)号：US20240352083A1

公开(公告)日：2024-10-24

申请号：US18647911

申请日：2024-04-26

Applicant: UCB Biopharma SRL

Inventor： Ralph Adams ,  Terence Seward Baker ,  Xiaofeng Liu

IPC: C07K14/54 ,  C07K14/505 ,  C07K14/535 ,  C07K14/55 ,  C07K16/18 ,  C07K16/24 ,  C07K16/28

CPC classification number: C07K14/5443 ,  C07K14/505 ,  C07K14/535 ,  C07K14/5428 ,  C07K14/55 ,  C07K16/18 ,  C07K16/244 ,  C07K16/248 ,  C07K16/2809 ,  C07K16/2818 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/76

Abstract: The present invention provides antibodies comprising a variable (V) domain and an insert polypeptide, wherein the insert polypeptide is within the framework 3 region of the V domain.

公开(公告)号：US12122839B2

公开(公告)日：2024-10-22

申请号：US18006484

申请日：2021-08-05

Applicant: Synthekine, Inc.

Inventor： Robert Kastelein ,  Deepti Rokkam ,  Patrick J. Lupardus

IPC: C07K16/28 ,  A61K39/00 ,  A61P37/02 ,  C07K14/715 ,  C07K16/46 ,  C12N15/63 ,  C12N15/86

CPC classification number: C07K16/2866 ,  A61P37/02 ,  C07K14/7155 ,  C07K16/2803 ,  C07K16/46 ,  C07K16/468 ,  C12N15/63 ,  C12N15/86 ,  A61K2039/505 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569

Abstract: Provided herein are IFNGR binding molecules that bind to IFNGR1 and IFNGR2 and comprise an anti-IFNGR2 sdAb and an anti-IFNGR2 VHH antibody.

公开(公告)号：US20240317857A1

公开(公告)日：2024-09-26

申请号：US18575698

申请日：2022-06-17

Applicant: AMPSOURCE BIOPHARMA SHANGHAI INC.

Inventor： Cui Wu ,  Yongjuan Gao ,  Li Zhou ,  Jiasheng Diao ,  Xinlu Ma ,  Zhao Dong ,  Qiang Li

IPC: C07K16/28 ,  A61P37/04 ,  C12N15/63

CPC classification number: C07K16/2809 ,  A61P37/04 ,  C12N15/63 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/74 ,  C07K2317/92

Abstract: Provided in the present invention is an antibody against human CD3 or an antigen-binding fragment thereof; also provided are a nucleic acid molecule encoding the antibody, an expression vector expressing the antibody and a host cell, as well as a method for producing the antibody. In addition, also provided in the present invention are a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, a use thereof in the preparation of a drug, and a use of the drug as a drug for the prevention and/or treatment of various diseases, including tumors, organ transplantation and autoimmune diseases.

公开(公告)号：US20240294633A1

公开(公告)日：2024-09-05

申请号：US18566522

申请日：2022-06-06

Applicant: NONAGEN THERAPEUTICS CORPORATION

Inventor： Charles J. ROSSER ,  Hideki FURUYA

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  G01N33/543

CPC classification number: C07K16/28 ,  A61P35/00 ,  G01N33/543 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/567

Abstract: Antibodies against human B cell lymphoma 6 protein (BCL-6) are provided. The antibodies have neutralizing activity against BCL-6. The anti-human B cell lymphoma 6 protein antibodies may be used in therapeutic treatment in patients with angiogenesis-dependent conditions.

公开(公告)号：US20240279327A1

公开(公告)日：2024-08-22

申请号：US18648653

申请日：2024-04-29

Applicant: Genentech, Inc.

Inventor： Germaine FUH ,  Chingwei V. LEE ,  Patrick KOENIG

IPC: C07K16/24 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  C07K16/46

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/247 ,  C07K16/468 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/92

Abstract: The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.

公开(公告)号：US12060416B2

公开(公告)日：2024-08-13

申请号：US17579376

申请日：2022-01-19

Applicant: SinoCellTech Ltd.

Inventor： Liangzhi Xie ,  Chunyun Sun ,  Rui Wang ,  Xiao Zhang

IPC: C07K16/22 ,  A61K39/00 ,  A61K47/68

CPC classification number: C07K16/22 ,  A61K47/6845 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention belongs to the field of tumor immunotherapy, and relates to a humanized monoclonal antibody that binds to VEGF. The present invention discloses nucleic acid sequences (including heavy/light chain variable regions) encoding said antibodies, and vectors, pharmaceutical compositions and kits containing said nucleic acid sequences. The antibody disclosed in the present invention can specifically bind to VEGF with high affinity and block the binding of VEGF to the receptor VEGFR2. Said antibodies also neutralize the proliferative effect of VEGF165 protein and multiple VEGF subtypes on HUVEC cells and can be used in clinical treatment of tumors, including but not limited to: colorectal cancer.

公开(公告)号：US20240228617A1

公开(公告)日：2024-07-11

申请号：US18405910

申请日：2024-01-05

Applicant: Immunocore Limited

Inventor： Jakub JAWORSKI ,  Kate ATKIN ,  Arnaud TECHINE ,  Vijaykumar KARUPPIAH ,  Florence SCHLOSSER ,  Ana PEREIRA RIBEIRO ,  Chandramouli CHILLAKURI ,  Nathaniel LIDDY ,  Andrew CREESE ,  Martin EBNER

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2809 ,  A61P35/00 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622

Abstract: The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PRAME peptide-HLA complex. In particular, the present invention relates to binding molecules that bind to PYLGQMINL (SEQ ID NO: 1) in complex with HLA-A24. The invention also relates to the use of such molecules for the treatment of malignant diseases.

公开(公告)号：US12030957B2

公开(公告)日：2024-07-09

申请号：US17115591

申请日：2020-12-08

Applicant: ProMab Biotechnologies, Inc. ,  Forevertek Biotechnology Co., Ltd

Inventor： Lijun Wu ,  Vita Golubovskaya

IPC: C07K14/725 ,  A61K35/17 ,  A61P35/00 ,  C07K14/705 ,  C07K16/28 ,  C07K16/40 ,  A61K39/00

CPC classification number: C07K16/40 ,  A61K35/17 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

Abstract: The present invention is directed to a chimeric antigen receptor (CAR) fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) comprising VH and VL, wherein scFv binds to human PLAP (placental alkaline phosphatase), (ii) a transmembrane domain, (iii) a co-stimulatory domain of CD28, OX-40, GITR, or 4-1BB, and (iv) CD3 an activating domain. The present invention is also directed to T cells, natural killer (NK) cells, or macrophages, modified to express the CAR of the present invention. The present invention is further directed to a method for treating PLAP-positive cancer cells by administering PLAP-CAR-T cells, PLAP-CAR-NK cells, or PLAP-CAR-macrophages to the patients.

公开(公告)号：US12030937B2

公开(公告)日：2024-07-09

申请号：US17376874

申请日：2021-07-15

Applicant: Janssen Biotech, Inc.

Inventor： Ellen Chi ,  Wilson Edwards ,  Matt Husovsky ,  Ann Lacombe ,  Christian Martinez ,  H. Mimi Zhou ,  John T. Lee

IPC: C07K16/28 ,  G01N33/50

CPC classification number: C07K16/28 ,  G01N33/5005 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/567 ,  G01N2333/705

Abstract: In certain aspects, the disclosure relates to anti-idiotype antibodies and antigen-binding portions thereof that specifically bind a GP5B83 containing protein, e.g., an antibody or antigen-binding portions thereof. In some aspects, the anti-idiotype antibodies and antigen-binding portions of the present disclosure can be used in methods to detect and quantify cells expressing chimeric antigen receptors that include GP5B83.

公开(公告)号：US12018073B2

公开(公告)日：2024-06-25

申请号：US16995428

申请日：2020-08-17

Applicant: GENSUN BIOPHARMA, INC.

Inventor： Margaret Karow ,  Jackie Sheng ,  Wei Zhang

IPC: A61K38/00 ,  C07K14/71 ,  C07K16/22 ,  C07K16/28

CPC classification number: C07K16/22 ,  C07K14/71 ,  C07K16/2818 ,  C07K16/2827 ,  A61K38/00 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/66 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2319/30

Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulators, angiogenesis pathway regulators and/or TGF pathway regulators are disclosed. Also disclosed are methods for treating proliferative disorders, infections, and immunological disorders with the antitumor antagonists described herein.